SEC Tracker
Get the app

GRAIL GRAL

GRAIL FY 2024: revenue $125.6M; diluted EPS −$63.54

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers GRAIL reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$125.6MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$2.0BNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$63.54No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$214.2MNo year-earlier figure tagged10-K balance sheet, on EDGAR
  5. Cash from operations−$577.2MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when GRAIL files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.

  1. Veracyte VCYT public float $1.7B, Jun 30, 2025
  2. CareDx CDNA public float $1.0B, Jun 30, 2025
  3. Caris Life Sciences CAI public float $3.9B, Jun 30, 2025
  4. RadNet RDNT public float $4.1B, Jun 30, 2025
  5. Guardant Health GH public float $6.2B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.